- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
BTI gets financing, reduces net loss
Magnetic source imaging developer Biomagnetic Technologies got some good news last month with word that it had secured a $1.5 million loan commitment from shareholder Dassesta International. BTI had been soliciting additional equity capital to stave off
Magnetic source imaging developer Biomagnetic Technologies got some good news last month with word that it had secured a $1.5 million loan commitment from shareholder Dassesta International. BTI had been soliciting additional equity capital to stave off a cash shortage (SCAN 1/21/98).
Further financing will be necessary, however. BTI is in the process of seeking additional equity capital from foreign investors to supplement the Dassesta loan, of which $895,000 has already been borrowed. Upon receipt of a minimum of $7 million of additional financing, BTI is obligated to repay the $1.5 million loan to Dassesta. Without additional financing in the near future, BTI will have difficulties operating as a going concern, according to the company.
In financial news, BTI reported fiscal second-quarter revenues of $1.7 million, up 11.6% compared with the $1.6 million reported in the same period last year. The firms net loss dropped to $597,000 for the period (end-March), compared with a net loss of $1.2 million in 1997.
BTI has also received an order for a Magnes 2500 Whole Head system from Tokyo Medical and Dental University in Japan, as well as acceptance of a system by the Institute pour la Recherche en Neurosciences et en Psychiatrie in Rouffach, France. The French site is employing the system for research on psychiatric patients, according to the company.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
